Board of Directors
Pierre Legault, M.B.A.
Chairman of the Board
Pierre Legault, M.B.A., CA, CPA, is Chairman of the Board and has served as a director of Poxel since March 2016. Mr. Legault also serves as a member of Syndax Pharmaceuticals, Iroko Pharmaceuticals and NephroGenex Boards. He previously served as Board member, Chairman of the audit committee of Tobira Therapeutics, Board member, Chairman and Chair of audit committee of Forest Laboratories, NPS Pharmaceuticals, Regado Pharmaceuticals, OSI Investment Holdings GMBH, Cyclacel Pharmaceuticals, Inc., The Jean Coutu Group (PJC) Inc. (and others). He served as Chief Executive Officer, President and Chief Financial Officer of several public companies including Eckerd Pharmacies, NephroGenex, OSI Pharmaceuticals, Rite Aid (and others), as well as Chief Executive Officer of Prosidion, Ltd., a mid-size U.K. biotechnology firm. Mr. Legault also held several senior positions with Sanofi-Aventis and predecessor companies, including President of Worldwide Dermatology Operations.
Mr. Legault studied at McGill University, University of Montreal (HEC) and the Harvard Business School, and holds a Six Sigma Green Belt, a B.A.A., M.B.A., CA and CPA diploma.
Chief Executive Officer of Cormedix
Mr. Baluch has built and led successful U.S. and international commercial teams in the primary care, specialty and hospital segments, launching leading products including Cialis, Byetta, Insulin devices, Cimzia, Vimpat and Neupro. During the 24 years Mr. Baluch worked for Eli Lilly & Co, he held international positions in general management, business development, market access and product leadership, and spanning Europe, the Middle East and the United States. At Lilly, as Diabetes Worldwide Franchise head, he had responsibility for guiding pipeline products from Phase 3 to completion on the market. He oversaw a team of nearly 130 people responsible for the medical, regulatory, legal, supply chain, marketing, pricing and reimbursement aspects of drug launches in the U.S. and globally. Following his tenure at Lilly, Mr. Baluch held multiple positions at UCB, the global biopharmaceutical company, as Senior Vice President & Chief Marketing Officer and most recently serving as Senior Vice President & President European Middle East & Africa (EMEA) Region.
Pascale Boissel, HEC Paris, Master in Management, CPA
Part-time CFO for Novadiscovery
Pascale Boissel is an advisor in finance, corporate structuring and operations with 25 years of experience. Ms. Boissel currently serves as part-time CFO for Novadiscovery, an innovative biotechnology company utilizing models and simulation to de-risk drug development. Previously, Ms. Boissel served as Deputy CEO and Head of Finance & Administration of the Technology Research Institute BIOASTER, an independent non-profit organization developing collaborative research programs in the fields of infectious disease and microbiology. In 2009, Ms. Boissel joined the biotechnology company Ipsogen and served as CFO, where she contributed to the reorganization of the company’s US operations and was responsible for significant financing activities. She also played a major role in the transaction that led to Ipsogen’s acquisition in 2011. Prior to Ipsogen, Ms. Boissel worked with publicly listed French groups and served as VP Finance in business control and group transactions. Ms. Boissel began her career in auditing and corporate finance consultancy at Price Waterhouse Coopers. She has extensive experience in international accounting and internal auditing standards.
Managing Director of Life Sciences for Hercules Technology Growth Capital
Janice Bourque is Managing Director of Life Sciences for Hercules Technology Growth Capital, a premier specialty finance company providing debt and equity to venture capital and private equity backed, and small cap public life science companies at all stages of development with $5.5 billion committed to more than 325 life science, technology and sustainable and renewable technology companies. Previously, she provided strategic corporate investor fundraising for Commons Capital and Oxford Bioscience Partners for innovative healthcare investments for emerging and developing countries and was Senior Vice President, Group Head-Life Sciences for Comerica Bank. She was President/CEO of the Massachusetts Biotechnology Council (MBC), which was at the forefront of the biotechnology revolution as the first biotechnology association in the world. Ms. Bourque is on several boards: Poxel Inc, The Village Bank, Commodore Builders, Forsyth Leadership Council, Emeritus Director of the MIT Koch Institute for Integrative Cancer Research Springboard Enterprises Life Science Council and is a member of the Women's Forum.
Ms. Bourque holds an M.B.A. in Finance and Accounting and a B.S. in Veterinary Science from the University of New Hampshire.
Thierry Hercend, M.D., Ph.D.
Venture Partner at EdRIP
Thierry Hercend has more than 30 years' experience in both academia and the pharmaceutical industry, in various therapeutic areas including oncology and inflammatory diseases. Since 2006, Dr. Hercend has been Venture Partner at Edmond de Rothschild Investment Partners (EdRIP). From 2002 to 2005, he was Vice President in charge of the oncology therapeutic area at Aventis. From 1998 to 2002, he was Vice President of Research, Europe at Vertex Pharmaceuticals. Previously, he was Head of Research and Development for the Laboratory of Plasma Fractionation and Biotechnology (LFB) and held various executive R&D positions with Roussel-Uclaf. Prior to joining the pharmaceutical industry, he was Head of the Hemato-Immunology Unit of the Gustave Roussy Cancer Institute, Villejuif, France; Director of Inserm Unit U333 dedicated to tumor immunology; and Professor of Immunology at the Medical Faculty of Paris XI University. Dr. Hercend has authored more than 120 publications in oncology, autoimmune diseases and transplantation.
Richard Kender, B.S., M.B.A.
Formerly Senior Vice-President Business Development and Licensing, Merck and Co. Inc., Independent Administrator
Richard Kender spent his entire career at Merck & Co., Inc. Mr. Kender started in accounting and finance roles of increasing responsibility and moved into corporate development in 1994. He was promoted to Vice President of Corporate Development in 1996 and in 2000, his responsibilities expanded to include Corporate Licensing and Worldwide Business Development, where he managed a department of approximately 70 people responsible for Merck's M&A, Licensing, Financial Evaluation and Analysis and Global Competitive Intelligence. His numerous achievements include leading a multidivisional team to create the Joint Venture Merial Animal Health with Sanofi-Aventis, the acquisition of 49% of shares of Banyu Pharmaceuticals in Japan, the spin-off and IPO of Medco and, most notably, in 2008, he played a key role in the $41 billion Schering Plough acquisition. Mr. Kender retired from Merck in September 2013.
Mr. Kender holds a B.S. in Accounting from Villanova University and an M.B.A. from Fairleigh Dickinson University.
Thomas Kuhn, Pharm.D., M.B.A.
Chief Executive Officer, Co-Founder
Thomas Kuhn joined Merck KGaA in 2000, where he held various positions in clinical development, largely in the area of diabetes. Between 2004 and 2007, Dr. Kuhn directed global R&D projects, with two products in Phase 2 clinical trials, and life cycle management projects, specifically for Glucophage®, the current reference in diabetes treatment. After the integration of Serono in 2007, he was involved in refining Merck Serono's strategy. With the decision to divest from diabetes as an integrated therapeutic area, Dr. Kuhn drove the project to relocate the diabetes assets, leading to the establishment of Poxel.
Dr. Kuhn holds a Pharmacy degree from the University of Lyon I (France) and an M.B.A. from Ashridge University (UK).
Olivier Martinez, Ph.D., M.B.A.
Investment Manager, Life Science team, CDC Entreprises
Olivier Martinez joined Bioam Gestion in 2000 as an Associate and became Investment Manager and member of the executive board in 2004. Following the integration of Bioam Gestion into CDC Entreprises in July 2010, Dr. Martinez is now in charge of managing investments of the InnoBio and Bioam funds. He currently serves on the boards of Cytheris, Adocia, Fab Pharma and Genticel. Prior to joining Bioam Gestion, Dr. Martinez spent two years working on healthcare projects in the Life Science Group of Gemini Consulting.
From 1992 to 1997, Dr. Martinez pursued his doctoral studies in cell biology at the Pasteur and Curie Institutes in Paris, followed by management training. He is an alumnus of the Ecole Normale Supérieure and holds a Ph.D. in Cell Biology from the University of Paris XI and a diploma from the Collège des Ingénieurs.
President and CEO of COSMO Public Relations Corporation
For over 30 years, Kumi Sato has served as President and CEO of Cosmo Public Relations Corporation, an award-winning strategic communications and public affairs firm based in Tokyo, Japan, with a specialized healthcare division, COSMO Healthcare. Since its founding, COSMO has consulted for over 500 companies in healthcare, food and food sciences, and the service industry. Before taking over as CEO in 1987, she founded COSMO International, which advised Japanese companies on US market entry strategies. During her time at COSMO, she has been instrumental in directing the company to broaden its international focus and has held a series of noteworthy advisor positions, such as President and Founder of Women Japan.com and Outside Director for Rokko & Associates Inc. In 2010, she founded BioCube, a think-tank to discuss Japan’s healthcare system and biotech-related topics. She currently serves as an advisor to the Global Health Innovative Technology Fund in Tokyo, a lecturer at the Graduate School of Business Breakthrough University and is Chairman Emeritus of the American Chamber of Commerce in Japan. In addition, she is co-chairman of the Global Council for the Asia Society, based in New York. Ms. Sato has also authored two business textbooks on communication strategies and corporate social responsibility. Ms Sato started her career at McKinsey & Co., New York and holds a B.A. in East Asian Studies from Wellesley College, MA.
Investment Director at EdRIP
Raphaël Wisniewski is investment director at Edmond de Rothschild Investment Partners (EdRIP) in the life sciences venture group. Mr. Wisniewski sits on the board of several European life sciences companies on behalf of EdRIP. Prior to joining EdRIP in 2001, Mr. Wisniewski spent several years in London working for the hospital group General Healthcare Group and in the corporate finance practices of Salomon Smith Barney and Goldman Sachs.